Highest-materiality recent filing
Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M
Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
Aytu BioPharma amends warrants to enable equity classification; expects liability reduction
Amended warrants from 2023 and 2025 offerings to clarify stockholder vote cannot change beneficial ownership blockers.
Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue
Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M
EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.
Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track
Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025
Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025
Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD
Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.
Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants
Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.
Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M
Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially
Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO
Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.
Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%
FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.
Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest
New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY
Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%
Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.
Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%
Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.
Aytu BioPharma receives FDA approval for Cotempla XR-ODT site transfer, expects margin boost in 2024
FDA approved Cotempla XR-ODT Prior Approval Supplement (PAS) for manufacturing transfer to contract manufacturer.
Aytu BioPharma COO resigns; company winding down manufacturing, suspending R&D
COO Christopher Brooke resigned effective Oct 13, 2023, to join a development-stage biotech.
Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%
Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).
Aytu submits Cotempla XR-ODT site transfer PAS to FDA; expects 15% margin improvement on ADHD brands
Submitted Cotempla XR-ODT Prior Approval Supplement to FDA; expects six-month review with approval by late 2023/early 2024.
Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.
Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M
Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.
Subleases 22,909 sq ft (~30%) of Grand Prairie, TX facility to AMTMS; base rent $20,045/mo through Dec 2023, then $21,000/mo until expansion.
Aytu BioPharma gets FDA approval for Adzenys site transfer; 15% margin improvement expected
FDA approved Prior Approval Supplement to transfer Adzenys XR-ODT manufacturing to contract manufacturer in 2023.
Preliminary discussions underway for potential strategic transactions and financing options.
Aytu BioPharma restates Q1 FY2023 financials; warrant misclassification adds $5.6M liabilities
Audit committee concludes Sep 30, 2022 financials should be restated due to warrant misclassification as equity instead of liabilities.
Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.
Aytu BioPharma enacts 1-for-20 reverse stock split to regain Nasdaq $1.00 bid compliance
1-for-20 reverse split reduces outstanding shares from ~68.8M to ~3.4M.
Settlement cancels 387,804 of 1,551,216 shares (25%) from 2021 option grants to directors and officers.
On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.
On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.
On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the “Company”), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company.
Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, the size of the Board will be increased from four (4) to five (5), and Abhinav Jain shall be appointed to the Board.
On December 22, 2022, Gary Cantrell, a member of the Board of Directors of Aytu BioPharma, Inc. (the “Company”), notified the Company of his intention to retire from the Company's Board of Directors, effective December 31, 2022.
Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer
On June 24 2022, the Board of Directors of Aytu BioPharma, Inc. (the “Company”) appointed Vivian Liu to the Board of Directors, effective July 1, 2022.
On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.
On December 8, 2021, Richard I. Eisenstadt resigned as Chief Financial Officer of Aytu BioPharma, Inc. (the “Company”), effective December 30, 2021, to pursue another opportunity at a development-stage pharmaceutical company.
On August 30, 2021, Steven J. Boyd resigned as a members of the board of directors of Aytu BioPharma, Inc. (the “Company”).
Max materiality 0.85 · Median 0.60 · Most common event other_material